Displaying drugs 8151 - 8175 of 13048 in total
CMG901
CMG901 is an anti-Claudin 18.2 monoclonal antibody conjugated with MMAE payload.
Investigational
Edodekin alfa
Edodekin alfa is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery).
Investigational
CRA_17693
Experimental
Matched Iupac: … (2R)-2-(5-{5-[amino(iminiumyl)methyl]-1H-1,3-benzodiazol-2-yl}-2'-fluoro-6-oxido-[1,1'-biphenyl]-3-yl …
CRA_17312
Experimental
Matched Iupac: … (3R)-3-[5-(6-carbamimidoyl-1H-1,3-benzodiazol-2-yl)-2'-methoxy-6-oxido-[1,1'-biphenyl]-3-yl]-3-carboxypropanoate …
CRA_10655
Experimental
Matched Iupac: … 2-{5-[amino(iminiumyl)methyl]-1H-1,3-benzodiazol-2-yl}-6-(cyclopentyloxy)benzen-1-olate …
MF101
MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation. MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal...
Investigational
Matched Description: … MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone …
CX157
CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous MAO-A inhibitors of this class.
Investigational
Matched Description: … of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous MAO-A ... CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor …
CGC-11047
CGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.
Investigational
Matched Description: … CGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis. …
ENMD-1198
Investigational
PD-166326
Experimental
Matched Iupac: … 6-(2,6-dichlorophenyl)-2-{[3-(hydroxymethyl)phenyl]amino}-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
KOSN-1724
KOSN-1724 is under investigation in clinical trial NCT01379287 (Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors).
Investigational
Matched Iupac: … (4S,7R,8S,9S,10Z,13Z,16S)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(1E)-1-(5-methyl-1,2-oxazol-3-yl)prop ... -1-en-2-yl]-1-oxacyclohexadeca-10,13-diene-2,6-dione …
GLPG-1205
GLPG-1205 is under investigation in clinical trial NCT03725852 (A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF)).
Investigational
Matched Iupac: … 9-(2-cyclopropylethynyl)-2-{[(2S)-1,4-dioxan-2-yl]methoxy}-4H,6H,7H-pyrimido[4,3-a]isoquinolin-4-one …
Matched Description: … GLPG-1205 is under investigation in clinical trial NCT03725852 (A Clinical Study to Test How Effective …
Matched Description: … GLPG-1205 is under investigation in clinical trial NCT03725852 (A Clinical Study to Test How Effective …
GLPG-1837
Investigational
Matched Iupac: … N-{3-carbamoyl-5,5,7,7-tetramethyl-4H,5H,7H-thieno[2,3-c]pyran-2-yl}-1H-pyrazole-3-carboxamide …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
PLX-R18
Investigational
CLBS12
CLBS12 is a GCSF-mobilized autologous cell therapy derived from CD34+ cells being investigated for the treatment of Buerger’s disease.
Investigational
Matched Description: … CLBS12 is a GCSF-mobilized autologous cell therapy derived from CD34+ cells being investigated for the …
VG161
VG161 is an oncolytic virus therapy under investigation for the treatment of cholangiocarcinoma.
Investigational
Matched Synonyms: … Recombinant human IL12/15-PDL1B HSV-1 oncolytic virus Injection …
RHCC10
RHCC10 is a recombinant human Clara cell protein.
Investigational
Matched Description: … RHCC10 is a recombinant human Clara cell protein. …
CRA_10991
Experimental
Matched Iupac: … 2-{5-[amino(iminiumyl)methyl]-6-chloro-1H-indol-2-yl}-6-(cyclopentyloxy)benzen-1-olate …
CRA_10762
Experimental
Matched Iupac: … 6-chloro-2-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1H-1,3-benzodiazole-5-carboximidamide …
RB106
Experimental
Matched Iupac: … (2S,5R)-5-phenyl-1-{2-[(2S)-3-phenyl-2-sulfanylpropanamido]acetyl}pyrrolidine-2-carboxylic acid …
CRA_10972
Experimental
Matched Iupac: … 6-chloro-2-[2-hydroxy-3-(2-methylpropoxy)phenyl]-1H-1,3-benzodiazole-5-carboximidamide …
CRA_11092
Experimental
Matched Iupac: … 6-fluoro-2-(2-hydroxy-3-{[(1S,2S)-2-methylcyclohexyl]oxy}phenyl)-1H-1,3-benzodiazole-5-carboximidamide …
CRA_10656
Experimental
Matched Iupac: … 2-{5-[amino(iminiumyl)methyl]-1H-1,3-benzodiazol-2-yl}-6-(2-methylpropoxy)benzen-1-olate …
TG-100801
TG100801 is a topically applied kinase inhibitor in macular degeneration patients. It is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological hallmarks of AMD and other back of the eye...
Investigational
Matched Iupac: … 4-chloro-3-[5-methyl-3-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2,4-benzotriazin-7-yl]phenyl benzoate …
Matched Description: … TG100801 is a topically applied kinase inhibitor in macular degeneration patients. …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Description: … TG100801 is a topically applied kinase inhibitor in macular degeneration patients. …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Displaying drugs 8151 - 8175 of 13048 in total